GPCBasedow: Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study

• Sponsor: Centre Hospitalier Universitaire, Amiens (Other)
• Overall Status: Completed
• CT.gov ID: NCT02798965
• Collaborator: (none)
• Enrollment: 52
• Location: 1
• Arms: 2
• Duration (Months): 41
• Patients Per Site Per Month: 1.3

Study Details

Study Description

Brief Summary

Lymphocytic thyroiditis is the most common autoimmune disease, usually affecting young women. Although the aetiology and pathogenesis remain obscure, the most widely accepted hypothesis is an interaction between a genetic predisposition and an environmental trigger factor such as viral infection. Parvovirus infections have been proposed as trigger factors for Hashimoto's thyroiditis and Graves' disease.

Condition or Disease	Intervention/Treatment	Phase
Graves Disease	Biological: serodiagnosis	N/A

Study Design

• Study Type: Interventional
• Actual Enrollment: 52 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Basic Science
• Official Title: Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study
• Study Start Date: Dec 1, 2010
• Actual Primary Completion Date: May 1, 2014
• Actual Study Completion Date: May 1, 2014

Arms and Interventions

Arm	Intervention/Treatment
Other: Control patients with goiter or nodule	Biological: serodiagnosis
Experimental: Graves' disease patients with Graves' disease	Biological: serodiagnosis

Outcome Measures

Primary Outcome Measures

1. prevalence of circulating parvovirus genome [Day 0]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 99 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Graves' disease :patients treated for Graves' disease, the diagnosis date less than 4 months

• Control : patients cared for nodules or goiter

Exclusion Criteria:

• Patients undergoing immunosuppressive therapy including corticosteroids

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	CHU Amiens	Amiens		France	80054

Sponsors and Collaborators

• Centre Hospitalier Universitaire, Amiens

Investigators

• Principal Investigator: Rachel DESAILLOUD, MD, PhD, CHU Amiens

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Centre Hospitalier Universitaire, Amiens
• ClinicalTrials.gov Identifier: NCT02798965
• Other Study ID Numbers: AOL10-DR-DESAILLOUD
• First Posted: Jun 14, 2016
• Last Update Posted: Jun 16, 2016
• Last Verified: Jun 1, 2016

• Keywords provided by Centre Hospitalier Universitaire, Amiens: parvovirus genome
• Additional relevant MeSH terms: Parvoviridae Infections; Graves Disease

Study Results

No Results Posted as of Jun 16, 2016